Marco Proietti1, Cécile Laroche2, Robby Nieuwlaat3, Harry J G M Crijns4, Aldo P Maggioni5, Deirdre A Lane1, Giuseppe Boriani6, Gregory Y H Lip7. 1. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom. 2. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France. 3. Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada. 4. Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands. 5. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France; ANMCO Research Center, Firenze, Italy. 6. Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, S. Orsola-Malpighi University Hospital, Bologna, Italy; Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. 7. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: g.y.h.lip@bham.ac.uk.
Abstract
BACKGROUND: In 2002, the European Society of Cardiology conducted the Euro Heart Survey (EHS), while in 2014concluded 1-year follow-up of the EURObservational Research Programme AF (EORP-AF) Pilot Registry. METHODS: We analysed differences in clinical profiles, therapeutic approaches and outcomes between these two cohorts after propensity score matching (PSM). RESULTS: After PSM, 5206 patients were analysed. In EORP-AF there were more elderly patients than EHS (p < .001). EORP-AF patients were more burdened with cardiovascular (CV) and non-CV comorbidities, with a higher proportion of patients with high thromboembolic risk. EORP-AF patients used more oral-anticoagulant (OAC) (p < .001). At 1-year follow-up EORP-AF patients had lower risk for thromboembolic and CV events, readmission for AF and other CV reasons (all p < .001), showing conversely a higher risk for CV death (p = .015). Kaplan-Meier curves showed that EORP-AF patients had higher risk for CV death (p < .0001) and all-cause death (p = .0019). Cox regression confirmed that EORP-AF patients were at higher risk for CV death (p = .021). CONCLUSIONS: We found significant changes in AF epidemiology over a decade in Europe, with older patients, more burdened with comorbidities. A greater use of OAC was found. Despite a reduction in risk for thromboembolic events, a high risk of CV-related death was still evident.
BACKGROUND: In 2002, the European Society of Cardiology conducted the Euro Heart Survey (EHS), while in 2014concluded 1-year follow-up of the EURObservational Research Programme AF (EORP-AF) Pilot Registry. METHODS: We analysed differences in clinical profiles, therapeutic approaches and outcomes between these two cohorts after propensity score matching (PSM). RESULTS: After PSM, 5206 patients were analysed. In EORP-AF there were more elderly patients than EHS (p < .001). EORP-AFpatients were more burdened with cardiovascular (CV) and non-CV comorbidities, with a higher proportion of patients with high thromboembolic risk. EORP-AFpatients used more oral-anticoagulant (OAC) (p < .001). At 1-year follow-up EORP-AFpatients had lower risk for thromboembolic and CV events, readmission for AF and other CV reasons (all p < .001), showing conversely a higher risk for CV death (p = .015). Kaplan-Meier curves showed that EORP-AFpatients had higher risk for CV death (p < .0001) and all-cause death (p = .0019). Cox regression confirmed that EORP-AFpatients were at higher risk for CV death (p = .021). CONCLUSIONS: We found significant changes in AF epidemiology over a decade in Europe, with older patients, more burdened with comorbidities. A greater use of OAC was found. Despite a reduction in risk for thromboembolic events, a high risk of CV-related death was still evident.
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: J Seelig; F W A Verheugt; M E W Hemels; L Illingworth; A Lucassen; H Adriaansen; M C M Bongaerts; M Pieterse; J P R Herrman; P Hoogslag; W Hermans; B E Groenemeijer; L V A Boersma; K Pieper; H Ten Cate Journal: Thromb J Date: 2020-03-30
Authors: Jakub Gumprecht; Magdalena Domek; Marco Proietti; Yan-Guang Li; Nidal Asaad; Wafa Rashed; Alawi Alsheikh-Ali; Mohammad Zubaid; Gregory Y H Lip Journal: J Clin Med Date: 2020-04-29 Impact factor: 4.241
Authors: Marco Proietti; Giulio Francesco Romiti; Brian Olshansky; Deirdre A Lane; Gregory Y H Lip Journal: J Am Heart Assoc Date: 2020-05-06 Impact factor: 5.501